Andere Sprachen X4 Pharmaceuticals, Inc.

Aktien

A2PFVY

US98420X1037

XFOR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
1,01 ^USD	+4,06 %		+11,84 %	+20,45 %

09.05.	Sektor-Update: Aktien des Gesundheitswesens steigen am späten Nachmittag	MT
09.05.	X4 Pharmaceuticals erhält $125 Millionen zusätzliches Kapital; Aktien steigen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Higher Late Afternoon	09.05.
X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise	09.05.
Transcript : X4 Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	07.05.
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
X4 PHARMACEUTICALS, INC. : HC Wainwright toujours à l'achat	30.04.
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	29.04.
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome	29.04.
Transcript : X4 Pharmaceuticals, Inc. - Special Call	29.04.
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	29.04.
Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024	21.03.
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21.03.
X4 PHARMACEUTICALS, INC. : B. Riley n'est plus acheteur	12.12.
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	09.12.
Transcript : X4 Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	09.11.
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
X4 Pharmaceuticals Insider Sold Shares Worth $181,573, According to a Recent SEC Filing	03.11.
X4 Pharmaceuticals Insider Sold Shares Worth $168,371, According to a Recent SEC Filing	03.11.
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome	31.10.23
X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors	18.10.23
Transcript : X4 Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 07:30 AM	13.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen X4 Pharmaceuticals, Inc.

Aktien

A2PFVY

US98420X1037

XFOR

Andere Sprachen

Filter